Adding immunotherapy to radiation improves disease-free survival in localized prostate cancer, phase III trial finds
https://cancerletter.com/clinical-roundup/20260605_9c/
Adding the investigational adenoviral-based viral immunotherapy aglatimagene besadenovec (alglatimagene, CAN-2409) to standard radiation therapy improved disease-free survival for patients with intermediate- or high-risk localized prostate cancer, according to the results of a multicenter clinical trial led by researchers at the Johns Hopkins University School of Medicine, Johns Hopkins Kimmel Cancer Center, Department of Radiation Oncology […]
